Pharma firms boost lobbying in race for coronavirus treatment, vaccine
- Gilead Sciences reports $1.26 million in lobbying spending in the three months ending June 30
- Moderna spends a company record $70,000 on lobbying in the second quarter, up from the $10,000 it spent in the same period a year ago